Compositions and systems for forming high strength medical sealants, and associated methods of preparation and use

• US 6,495,127 B1
• Filed: 08/28/2000
• Issued: 12/17/2002
• Est. Priority Date: 08/27/1999
• Status: Expired due to Term

• Current Assignee: Angiodevice International GmbH
• Original Assignee: Cohesion Technologies Inc. (Angiotech Pharmaceuticals Incorporated)
• Inventors: Wallace, Donald G., Chu, George H., Schroeder, Jacqueline Anne
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): FUBARA, BLESSING M
• Application Number:
  US09/649,337
• Time in Patent Office: 841 Days
• Field of Search: 424/78.03, 424/422, 424/78.02, 424/443, 424/445, 424/486, 424/423, 424/424
• US Class Current: 424/78.03
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/418 Agents promoting blood coagulation, blood-clotting agents, embolising agents
• CPC Class Codes: A61L 24/0015 Medicaments; Biocides
• CPC Class Codes: A61L 24/0026 Sprayable compositions
• CPC Class Codes: A61L 24/0031 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 24/046 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L24/043 takes precedence
• CPC Class Codes: C08G 65/329 with organic compounds
• CPC Class Codes: C08G 75/045 from mercapto compounds and unsaturated compounds
• CPC Class Codes: C08G 75/26 Polythioesters
• CPC Class Codes: C08L 71/00 Compositions of polyethers obtained by reactions forming an ether link in the main chain of polyacetals C08L59/00; of epoxy resins C08L63/00; of polythioether-ethers C08L81/02; of polyether-sulfones C08L81/06; Compositions of derivatives of such polymers
• CPC Class Codes: C08L 71/02 Polyalkylene oxides
• CPC Class Codes: C08L 81/02 Polythioethers; Polythioether-ethers
• CPC Class Codes: C08L 89/06 derived from leather or skin , e.g. gelatin
• CPC Class Codes: Y10S 977/914 Protein engineering

Abstract

The present invention relates generally to synthetic polymer compositions that form interpenetrating polymer networks. In a preferred embodiment, the compositions comprise two multifunctionally activated synthetic polymers, along with a tensile strength enhancer. Such compositions form matrices that exhibit superior cohesive strength and in many instances can serve as adequate replacements for surgical means of attaching tissues, such as sutures and medical staples.

Claims

1. A composition for forming a matrix useful as a high strength medical sealant, wherein said matrix-forming composition comprises:

a) a first multifunctional synthetic polymer having a core and m functional groups, X;

b) a multifunctional crosslinker having n functional groups, Y, wherein the sum of m and n is greater than or equal to 5, and X and Y react to form a covalent crosslink Z upon admixture of the first multifunctional synthetic polymer and the multifunctional crosslinker; and

c) a tensile strength enhancer comprised of a fibrous material selected from the group consisting of polyglycolide, polylactide, polyglycolide-polylactide copolymers, glass wool, plastics, resins, and combinations thereof,

wherein the high strength medical sealant formed by reaction of the first multifunctional synthetic polymer with the multifunctional crosslinker has at least 10% of the tensile strength of cyanoacrylate.

2. The composition according to claim 1, wherein the multifunctional crosslinker is a second multifunctional synthetic polymer.

3. The composition according to claim 2, wherein at least one of the first or second multifunctional synthetic polymers further comprises a chain extender.

4. The composition according to claim 3, wherein the chain extender is comprised of a biodegradable material.

5. The composition according to claim 4, wherein the chain extender biodegrades at a faster rate in situ than the first and second multifunctional synthetic polymers.

6. The composition according to claim 4, wherein the chain extender is an alpha-hydroxy acid, a poly(lactone), a poly(orthocarbonate) or a poly(phosphoester).

7. The composition according to claim 4, wherein the first and second multifunctional synthetic polymers biodegrade at a faster rate in situ than the chain extender.

8. The composition according to claim 4, wherein the chain extender is enzymatically degradable.

9. The composition according to claim 1, further comprising a rigid nanofiber.

10. The composition according to claim 9, wherein the nanofiber is comprised of a biopolymer.

11. The composition according to claim 10, wherein the biopolymer is selected from the group consisting of methylated collagen, tubulin and keratin.

12. The composition according to claim 11, wherein the biopolymer is methylated collagen.

13. The composition according to claim 1, further comprising an additional compound selected from the group consisting of glycosaminoglycans, proteins, and peptide fragments.

14. The composition according to claim 13, wherein the additional compound is a protein.

15. The composition according to claim 14, wherein the protein is collagen, fibronectin, gelatin, albumin, or peptide fragments thereof.

16. The composition according to claim 15, wherein the protein is collagen.

17. The composition according to claim 16, wherein the collagen is afibrillar, microfibrillar or fibrillar collagen.

18. The composition according to claim 16, wherein the collagen is Type I collagen.

19. The composition according to claim 16, wherein the collagen is Type III collagen.

20. The composition according to claim 16, wherein the collagen is esterified.

21. The composition according to claim 20, wherein the collagen is methylated, ethylated, propylated or benzylated collagen.

22. The composition according to claim 20, wherein the collagen is methylated collagen.

23. The composition according to claim 13, wherein the additional compound is a glycosaminoglycan.

24. The composition according to claim 23, wherein the glycosaminoglycan is selected from the group consisting of hyaluronic acid, chitin, chondroitin sulfate A, B or C, keratin sulfate, keratosulfate and heparin.

25. The composition according to claim 1, further comprising an antibiotic, a growth factor or a hemostatic agent.

26. The composition according to claim 1, wherein m and n are each 4 or greater.

27. The composition according to claim 1, wherein the tensile strength enhancer is selected from the group consisting of polyglycolide, polylactide and copolymers thereof.

28. The composition according to claim 27, wherein the tensile strength enhancer is polyglycolide.

29. The composition according to claim 27, wherein the tensile strength enhancer is polylactide.

30. The composition according to claim 27, wherein the tensile strength enhancer is a polyglycolide-polylactide copolymer.

31. The composition according to claim 30, wherein the polyglycolide-polylactide copolymer has a glycolide-lactide ratio of approximately 90:

10.

32. The composition according to claim 1, wherein X is sulfhydryl and Y is a sulfhydryl-reactive group.

33. The composition according to claim 32, wherein the sulfhydryl-reactive group is selected to form a thioether, thioester, imido-thioester, or disulfide bond upon reaction with a sulfhydryl group.

34. The composition according to claim 33, wherein the sulthydryl-reactive group is maleimido, succinimidyl, acrylate, or epoxy.

35. The composition according to claim 1, wherein X is amino and Y is an amino-reactive group.

36. The composition according to claim 35, wherein the amino-reactive group is succinimidyl or acrylate.

37. The composition according to claim 32 or claim 35, further comprising a buffer solution that maintains the composition at an acidic pH effective to prevent reaction between the first multifunctional synthetic polymer and the multifunctional crosslinker.

38. The composition according to claim 37, wherein the acidic pH is in the range of 2 to 4.

39. A method for providing a high strength medical sealant on a surface, comprising:

providing the composition of claim 1;

adding a pH-increasing activator to the composition to provide a pH sufficiently high to enable reaction between the first multifunctional synthetic polymer and the multifunctional crosslinking agent; and

applying the activated composition to the surface.

40. The method of claim 39, wherein the pH-increasing activator is a basic buffer solution.

41. A method for effecting the nonsurgical attachment of a first tissue surface to a second tissue surface, comprising:

(a) applying the composition of claim 1 to the first tissue surface; and

(b) contacting the firs+tissue surface with the second tissue surface to effect adhesion therebetween.

42. A method for applying a sealing layer to a native tissue surface, comprising applying the composition of claim 1 to the native tissue surface and allowing reaction to occur between the first multifunctional synthetic polymer and the multifunctional crosslinking agent.

43. A method for effecting surgical adhesion, comprising applying the composition of claim 1 to a wound or suture and allowing reaction to occur between the first multifunctional synthetic polymer and the multifunctional crosslinking agent.

44. A method for providing a sealant coating on the surface of a synthetic implant, comprising applying the composition of claim 1 to the surface of the synthetic implant, and allowing reaction to occur between the first multifunctional synthetic polymer and the multifunctional crosslinking agent.

45. A composition for forming a matrix useful as a high strength medical sealant, wherein said matrix-forming composition comprises:

a) a polyalkylene oxide having n nucleophilic groups, X;

b) a polyalkylene oxide having n electrophilic groups, Y, wherein the sum of m and n is greater than or equal to 5, and X and Y react to form a covalent crosslink Z upon admixture of a) and b) under crosslinking conditions;

c) a rigid nanofiber; and

d) a fibrous tensile strength enhancer, and

wherein the high strength medical sealant formed by reaction of a) and b) has at least 10% of the tensile strength of cyanoacrylate.

46. The composition according to claim 45, wherein the rigid nanofiber comprises methylated collagen.

47. A biocompatible polymer device for use in treating tissues comprising a collagen sponge or sheet incorporated with a two-part reactive polyethylene glycol powder, wherein said reactive powder further comprises a first polyethylene glycol having multiple nucleophilic groups and a second polyethylene glycol having multiple electrophilic groups, wherein the polyethylene glycol powder remains unreactive until contacted with a high pH buffer.

48. A system for forming a high strength medical sealant, comprising:

a) a first multifunctional synthetic polymer having a core and m functional groups, X;

b) a multifunctional crosslinker having n functional groups, Y, wherein X and Y react to form a covalent crosslink Z upon admixture of the first multifunctional synthetic polymer and the multifunctional crosslinker, and further wherein the first multifunctional synthetic polymer and the multifunctional crosslinker are physically separated from each other until reaction therebetween is desired;

c) a tensile strength enhancer comprised of fibers 5 to 40 microns in diameter and 20 to 5000 microns in length and having a glass transition temperature above 37°

C.; and

d) a rigid nanofiber,

wherein the high strength medical sealant formed upon reaction of the first multifunctional synthetic polymer and the multifunctional crosslinker has at least 10% of the tensile strength of cyanoacrylate.

49. The system according to claim 48, wherein the multifunctional crosslinker is a second multifunctional synthetic polymer.

50. The system according to claim 49, wherein at least one of the first or second multifimctional synthetic polymers further comprises a chain extender.

51. The system according to claim 50, wherein the chain extender is comprised of a biodegradable material.

52. The system according to claim 51, wherein the chain extender biodegrades at a faster rate in situ than the first and second multifunctional synthetic polymers.

53. The system according to claim 51, wherein the chain extender is an alpha-hydroxy acid, a poly(lactone), a poly(orthocarbonate) or a poly(phosphoester).

54. The system according to claim 51, wherein the first and second multifunctional synthetic polymers biodegrade at a faster rate in situ than the chain extender.

55. The system according to claim 51, wherein the chain extender is enzymatically degradable.

56. The system according to claim 48, further comprising an additional compound selected from the group consisting of glycosaminoglycans, proteins, and peptide fragments.

57. The system of claim 56, wherein the additional compound is a protein.

58. The system according to claim 57, wherein the protein is collagen, fibronectin, gelatin, albumin, or peptide fragments thereof.

59. The system according to claim 58, wherein the protein is collagen.

60. The system according to claim 59, wherein the collagen is afibrillar, microfibrillar or fibrillar collagen.

61. The system according to claim 59, wherein the collagen is Type I collagen.

62. The system according to claim 59, wherein the collagen is Type III collagen.

63. The system according to claim 59, wherein the collagen is esterified.

64. The system according to claim 63, wherein the collagen is methylated, ethylated, propylated or benzylated collagen.

65. The system according to claim 56, wherein the additional compound is a glycosaminoglycan.

66. The system according to claim 65, wherein the glycosaminoglycan is selected from the group consisting of hyaluronic acid, chitin, chondroitin sulfate A, B or C, keratin sulfate, keratosulfate and heparin.

67. The system according to claim 48, wherein X is sulfhydryl and Y is a sulfhydryl-reactive group.

68. The system according to claim 67, wherein the sulfhydryl-reactive group is selected to form a thioether, thioester, imido-thioester, or disulfide bond upon reaction with a sulfhydryl group.

69. The system according to claim 68, wherein the sulfhydryl-reactive group is maleimido, succinimidyl, acrylate, or epoxy.

70. The system according to claim 48, wherein X is amino and Y is an amino-reactive group.

71. The system according to claim 70, wherein the amino-reactive group is succinimidyl or acrylate.

72. The system according to claim 48, wherein at least one of the first multifunctional synthetic polymer and the multifunctional crosslinking agent is in an aqueous solution.

73. The system according to claim 48, wherein the nanofiber is comprised of a biopolymer.

74. The system of claim 73, wherein the biopolymer is selected from the group consisting of methylated collagen, tubulin and keratin.

75. The system of claim 74, wherein the biopolymer is methylated collagen.

76. A method for providing a high strength medical sealant on a surface, comprising:

providing the system of claim 48;

adding a pH-increasing activator to the composition to provide a pH sufficiently high to enable reaction between the first multifunctional synthetic polymer and the multifunctional crosslinking agent; and

applying the activated composition to the surface.

77. The method of claim 76, wherein the pH-increasing activator is a basic buffer solution.

78. A method for effecting the nonsurgical attachment of a first tissue surface to a second tissue surface, comprising:

(a) applying the system of claim 48 to the first tissue surface; and

(b) contacting the first tissue surface with the second tissue surface to effect adhesion therebetween.

79. A method for applying a sealing layer to a native tissue surface, comprising applying the system of claim 48 the native tissue surface and allowing reaction to occur between the first multifunctional synthetic polymer and the multifimctional crosslinking agent.

80. A method for effecting surgical adhesion, comprising applying the system of claim 48 to a wound or suture and allowing reaction to occur between the first multifunctional synthetic polymer and the multifunctional crosslinking agent.

81. A method for providing a sealant coating on the surface of a synthetic implant, comprising applying the system of claim 48 to the surface of the synthetic implant, and allowing reaction to occur between the first multifunctional synthetic polymer and the multifunctional crosslinking agent.